TherapeuticsMD
TXMD
53 hedge funds and large institutions have $200M invested in TherapeuticsMD in 2013 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 6 closing their positions.
1,390% more capital inflows, than outflows
Capital inflows: $40.3M | Capital outflows: $2.71M
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
13% more funds holding
Funds holding: 47 → 53 (+6)
11.96% more ownership
Funds ownership: 40.18% → 52.14% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$12.7M |
| 2 |
Gilder Gagnon Howe & Co
New York
|
+$6.67M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.34M |
| 4 |
Broadfin Capital
New York
|
+$5.15M |
| 5 |
Deerfield Management
New York
|
+$3.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$944K |
| 2 |
Flow Traders U.S.
New York
|
-$378K |
| 3 |
Goldman Sachs
New York
|
-$293K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$287K |
| 5 |
Citigroup
New York
|
-$160K |
TXMD Hedge Fund Activity: Q3 2013 in Review
53 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q3 2013, worth a combined $200M — up 26% from $160M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new TXMD positions and 6 closed out — a net gain of 6 holders — while 22 added to existing stakes and 17 trimmed.
The largest buyer was RA Capital Management, adding an estimated $12.7M. The largest seller was Sabby Management, exiting entirely with an estimated $944K sold.
- 53 institutional investors held TherapeuticsMD (TXMD) as of Q3 2013, up from 47 in Q2 2013.
- Funds reported $200M of TherapeuticsMD stock for Q3 2013, up 26% quarter-over-quarter.
- 12 funds opened new TherapeuticsMD positions in Q3 2013 and 6 closed out, a net change of +6 holders.
- The largest TherapeuticsMD buyer in Q3 2013 was RA Capital Management, an estimated $12.7M added.
- The largest TherapeuticsMD seller in Q3 2013 was Sabby Management, an estimated $944K sold.
Based on aggregated 13F filings for Q3 2013.